Depression during pregnancy

New England Journal of Medicine

Volumn 365, Issue 17, 2011, Pages 1605-1611

  Stewart, Donna E ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; DESVENLAFAXINE; DULOXETINE; MIRTAZAPINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; CASE REPORT; COGNITIVE THERAPY; DEPRESSION; DISEASE DURATION; DRUG DOSE INCREASE; ELECTROCONVULSIVE THERAPY; FATIGUE; FEMALE; GESTATION PERIOD; HUMAN; INSOMNIA; MAJOR DEPRESSION; MARRIED WOMAN; MEDICAL HISTORY; MENTAL CONCENTRATION; PATIENT MONITORING; PREGNANCY; PRIORITY JOURNAL; PUERPERAL DEPRESSION; SUICIDE ATTEMPT; MULTIMODALITY CANCER THERAPY; PRACTICE GUIDELINE; PREGNANCY COMPLICATION; PSYCHOTHERAPY;

ANTIDEPRESSIVE AGENTS; COMBINED MODALITY THERAPY; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; PREGNANCY COMPLICATIONS; PSYCHOTHERAPY; SERTRALINE; YOUNG ADULT;

EID: 80054938852     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcp1102730     Document Type: Article

References (50)

1. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289:3095-105. (Pubitemid 37432885)
2. Gavin NI, Gaynes BN, Lohr KN, Meltzer- Brody S, Gartlehner G, Swinson T. Perinatal depression: a systematic review of prevalence and incidence. Obstet Gynecol 2005;106:1071-83.
3. Bennett HA, Einarson A, Taddio A, Koren G, Einarson TR. Prevalence of depression during pregnancy: systematic review. Obstet Gynecol 2004;130:698-709. [Erratum, Obstet Gynecol 2004;103:1344.]
4. Diagnostic and statistical manual of mental disorders, 4th ed.: DSM-IV. Washington, DC: American Psychiatric Association, 1994.
5. Practice guideline for the treatment of patients with major depressive disorder. 3rd ed. Washington, DC: American Psychiatric Association, 2010:66-70.
6. Dietz PM, Williams SB, Callaghan WM, Bachman DJ, Whitlock EP, Hornbrook MC. Clinically identified maternal depression before, during, and after pregnancies ending in live births. Am J Psychiatry 2007;164:1515-20. (Pubitemid 350069730)
7. Antenatal and postnatal mental health: the NICE guideline on clinical management and service guidance. London: National Institute for Health and Clinical Excellence, 2007. (http://www.nice.org .uk/CG045fullguideline.)
8. Yonkers KA, Wisner KL, Stewart DE, et al. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen Hosp Psychiatry 2009; 31:403-13.
9. Davis EP, Glynn LM, Dunkel Schetter C, Hobel C, Chicz-Demet A, Sandman CA. Prenatal exposure to prenatal depression and cortisol influences infant temperament. J Am Acad Child Adolesc Psychiatry 2007;46:737-46. (Pubitemid 46816827)
10. Leech SL, Larkby CA, Day R, Day NL. Predictors and correlates of high levels of depression and anxiety symptoms among children at age 10. J Am Acad Child Adolesc Psychiatry 2006;45:223-30. (Pubitemid 43151527)
11. Field T, Diego M, Hernandez-Reif M. Prenatal depression effects on the fetus and newborn: a review. Infant Behav Dev 2006;29:445-55. (Pubitemid 43811827)
12. Vos T, Haby MM, Barendregt JJ, Kruijshaar M, Corry J, Andews G. The burden of major depression avoidable by longer-term treatment strategies. Arch Gen Psychiatry 2004;61:1097-103. (Pubitemid 39463410)
13. Patten SB. A major depression prognosis calculator based on episode duration. Clin Pract Epidemiol Ment Health 2006;2:13-21.
14. American College of Obstetricians and Gynecologists Committee on Obstetric Practice. Committee opinion no. 453: screening for depression during and after pregnancy. Obstet Gynecol 2010;115:394-5.
15. Cox J, Holden J. Perinatal psychiatry: use and misuse of the Edinburgh Postnatal Depression Scale. London: Royal College of Psychiatrists, 1994.
16. Spitzer RL, Williams J, Kroenke K, Hornyak R, McMurray J. Validity and utility of the PRIME-MD Patient Health Questionnaire in assessment of 3000 obstetric- gynecologic patients: The PRIME-MD Patient Health Questionnaire Obstetrics- Gynecology Study. Am J Obstet Gynecol 2000;183:759-69.
17. Grote NK, Bridge JA, Gavin AR, Melville JL, Iyengar S, Katon WJ. A meta-analysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction. Arch Gen Psychiatry 2010;67:1012-24.
18. Deave T, Heron J, Evans J, Emond A. The impact of maternal depression in pregnancy on early child development. BJOG 2008;115:1043-51. (Pubitemid 351841766)
19. Lattimore KA, Donn SM, Kaciroti N, Kemper AR, Neal CR Jr, Vazquez DM. Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and effects on the fetus and newborn: a meta-analysis. J Perinatol 2005;25:595-604. (Pubitemid 43118131)
20. Rahimi R, Nikfar S, Abdollahi M. Pregnancy outcomes following exposure to serotonin reuptake inhibitors: a metaanalysis of clinical trials. Reprod Toxicol 2006;22:571-5. (Pubitemid 44592550)
21. Bar-Oz B, Einarson T, Einarson A, et al. Paroxetine and congenital malformations: meta-analysis and consideration of potential confounding factors. Clin Ther 2007;29:918-26. (Pubitemid 47223423)
22. Pedersen LH, Henriksen TB, Vestergaard M, Olsen J, Bech BH. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ 2009;339:b3569.
23. Reis M, Källén B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 2010;40:1723-33.
24. Malm H, Artama M, Gissler M, Ritvanen A. Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Obstet Gynecol 2011;118:111- 20.
25. Udechuku A, Nguyen T, Hill R, Szego K. Antidepressants in pregnancy: a systematic review. Aust N Z J Psychiatry 2010;44:978-96.
26. Cooper WO, Willy ME, Pont SJ, Ray WA. Increasing use of antidepressants in pregnancy. Am J Obstet Gynecol 2007; 196:544-55.
27. Headley J, Northstone K, Simmons H, Golding J. Medication use during pregnancy: data from the Avon Longitudinal Study of Parents and Children. Eur J Clin Pharmacol 2004;60:355-61. (Pubitemid 39062322)
28. Hemels ME, Einarson A, Koren G, Lanctot KL, Einarson TR. Antidepressant use during pregnancy and rates of spontaneous abortion: a meta-analysis. Ann Pharmacother 2005;39:803-9. (Pubitemid 40570656)
29. Simon GE, Cunningham ML, Davis RL. Outcomes of prenatal antidepressant exposure. Am J Psychiatry 2002;159:2055-61. (Pubitemid 35423865)
30. Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 2007;356:2684-92.
31. Wurst KE, Poole C, Ephrose SA, Olshan AF. First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studies. Birth Defects Res A Clin Mol Teratol 2010;88:159-70.
32. Diav-Citrin O, Shechtman S, Weinbaum D, et al. Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. Br J Clin Pharmacol 2008;66:695-705.
33. Louik C, Lin AE, Werler MM, Hernández- Díaz S, Mitchell AA. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 2007;356:2675-83.
34. Suri R, Altshuler L, Hellemann G, Burt VK, Aquino A, Mintz J. Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth. Am J Psychiatry 2007;164:1206-13. (Pubitemid 47292409)
35. Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population- based linked health data. Arch Gen Psychiatry 2006;63:898-906. (Pubitemid 44188483)
36. Oberlander TF. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Res B Dev Reprod Toxicol 2008;83:68-76. (Pubitemid 351317794)
37. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996;335:1010-5. (Pubitemid 26338730)
38. Costei AM, Kozer E, Ho T, Ito S, Koren G. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med 2002;156:1129-32. (Pubitemid 36343460)
39. Chambers CD, Hernández-Díaz S, Van Marter LJ, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006;354:579-87. (Pubitemid 43209105)
40. Croen LA, Grether JK, Yoshida CK, Odouli R, Hendrick V. Antidepressant use during pregnancy and childhood autism spectrum disorders. Arch Gen Psychiatry 2011 July 4 (Epub ahead of print).
41. Dennis CL, Ross LE, Grigoriadis S. Psychosocial and psychological interventions for treating antenatal depression. Cochrane Database Syst Rev 2007;3:CD006309.
42. Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant drug effects and depression severity: a patient-level metaanalysis. JAMA 2010;303:47-53.
43. Cohen L, Alshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 2006; 295:499-507. [Erratum, JAMA 2006;296: 170.] (Pubitemid 43200344)
44. Anderson EL, Reti IM. ECT in pregnancy: a review of the literature from 1941 to 2007. Psychosom Med 2009;71:235-42.
45. Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C. Effects of timing and duration of gestational exposure to serotonin reuptake inhibitors: population- based study. Br J Psychiatry 2008; 192:338-43. (Pubitemid 351692377)
46. Dennis CL, Allen K. Interventions (other than pharmacological, psychosocial, or psychological) for treating antenatal depression. Cochrane Database Syst Rev 2008;4:CD006795.
47. Dimidjian S, Goodman S. Nonpharmacologic intervention and prevention strategies for depression during pregnancy and the postpartum. Clin Obstet Gynecol 2009;52:498-515.
48. Linde K, Berner M, Kriston L. St John's wort for major depression. Cochrane Database Syst Rev 2008;4:CD000448.
49. Oberlander TF, Bonaguro RJ, Misri S, Papsdorf M, Ross CJ, Simpson EM. Infant serotonin transporter (SLC6A4) promoter genotype is associated with adverse neonatal outcomes after prenatal exposure to serotonin reuptake inhibitor medications. Mol Psychiatry 2008;13:65-73. (Pubitemid 350275180)
50. Robertson E, Grace S, Wallington T, Stewart DE. Antenatal risk factors for post-partum depression: a synthesis of recent literature. Gen Hosp Psychiatry 2004;26: 289-95. (Pubitemid 38962393)